Rao Mushtaq is an Oncology physician affiliated with University of Colorado Denver. OpenAlex indexes 22 publications with 309 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9451 Huron St
Thornton, CO 802605426
Telephone
303-650-4042Provider last certified this registry record 18 Nov 2020.
Industry payments
60 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Incyte CorporationProgram year20251 payment
- GlaxoSmithKline, LLC.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
28.6%Factor Xa inhibitor21%Eliquis58%Xarelto42%Part D<11 patientsLow Molecular Weight Heparin7.6%Enoxaparin Sodium100%Part D<11 patientsMetabolism & gastrointestinal
21%Proton pump inhibitor9.5%Pantoprazole Sodium52%Omeprazole48%Part D<11 patientsCorticosteroid6.9%Prednisone100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
20.6%Antimetabolite9.9%Hydroxyurea100%Part D<11 patientsKinase inhibitor6.1%Jakafi100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer—an IMMUNOTARGET case series
Translational Lung Cancer Research
2022 - Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors
Journal of the National Comprehensive Cancer Network
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Nanette Santoro, MD
University of Colorado Denver
Gary Larsen, MD
University of Colorado Denver
Jonathan Gutman, MD
University of Colorado Denver
Lindsay Boyers, MD
University of Colorado Denver
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”